What You’ll Be Able To Do
- Describe TB-500’s confirmed mechanisms: G-actin sequestration, F-actin polymerization, and directed cell migration — and distinguish these from full TB-4 biology
- Identify appropriate clinical scenarios: chronic tendinopathy, non-healing wounds, and post-surgical recovery after failure of standard care
- Design protocols with clear separation between oral liposomal combo formulations (BPC-157 + TB-500) and compounded SubQ injectable pathways
- Apply mandatory screening: active malignancy (angiogenesis risk), WADA prohibited status (S2 class), and performance-enhancement framing (decline and document)
- Articulate the TB-500/TB-4 distinction in patient consent and clinical documentation
Clinical Focus Areas
Soft Tissue Repair — Chronic tendinopathy, ligament injury, fascial tears refractory to PT, PRP, and corticosteroid injection. The most defensible clinical application.
Non-Healing Wounds — Chronic venous ulcers, diabetic wounds, post-surgical wounds failing standard wound care. Phase 2 trial data showed ~30-day healing acceleration.
Post-Surgical Recovery — Adjunctive tissue healing when standard rehabilitation has plateaued. Requires documented failure of conventional care.
Neuropathic Pain — Refractory pain syndromes. Indirect mechanism — weaker mechanistic basis. Research-adjacent contexts only.
Important Notes on Delivery
TB-500 is available as a SubQ injectable (compounded) and as an oral liposomal combination supplement (BPC-157 + TB-500). Standalone oral liposomal TB-500 is not mechanistically supported — the mechanism requires systemic vascular delivery. The oral combo formulation is addressed in terms of its synergistic rationale, with transparent disclosure that no human bioavailability data exists for the oral TB-500 component.
For the regulatory, risk-management, and practice-management frameworks that apply across all peptide pathways — see the Foundations course.
Who This Is For
Clinicians managing refractory musculoskeletal injury, non-healing wounds, or post-surgical recovery after standard care has been exhausted. TB-500 is classified as intermediate-to-advanced complexity.
Prerequisite: CSI Foundations (complimentary)
Course Details
Format: Self-paced, interactive online module via Reach 360
Time to Complete: Approximately 1 hour
Lessons: 7
Price: $199
Includes: Dosing & Protocol Desk Guide, Clinical Decision Tree, Evidence Reference Card, Competency Assessment
